Velcade - Bortezomib for injection - MILLENNIUM - Proteasome Inhibitor approved for treatment of relapsed mantle cell lymphoma

被引：0
|
作者：
不详
机构：
来源：
FORMULARY | 2007年 / 42卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：11 / 12
页数：2
相关论文
共 50 条
  • [1] Promising activity of the proteasome inhibitor bortezomib (velcade) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
    O'Connor, O
    Wright, J
    Moskowitz, CH
    Muzzy, J
    MacGregor-Cortelli, B
    Hamlin, P
    Straus, D
    Trehu, E
    Schenkein, DP
    Zelenetz, AD
    [J]. BLOOD, 2003, 102 (11) : 636A - 636A
  • [2] The effect of proteasome inhibitor with Bortezomib (Velcade™) in B-cell lymphoma cell lines
    Strauss, SJ
    Lui, W
    Schenkein, D
    Shringarpure, R
    Anderson, K
    Lister, TA
    Joel, SP
    [J]. BLOOD, 2003, 102 (11) : 903A - 903A
  • [3] Velcade - Bortezomib for injection - Millennium - Multiple myeloma treatment represents new class: proteasome inhibitori
    不详
    [J]. FORMULARY, 2003, 38 (06) : 346 - +
  • [4] Marked clinical activity of the novel proteasome inhibitor bortezomib in patients with relapsed follicular and mantle cell lymphoma
    O'Connor, Owen A.
    [J]. ANNALS OF ONCOLOGY, 2004, 15 : 152 - 152
  • [5] Bortezomib (velcade) for the treatment of relapsed classical Hodgkin lymphoma
    Younes, A
    Pro, B
    Fayad, L
    Dang, N
    Romaguera, J
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 210 - 210
  • [6] Report of a phase II study of proteasome inhibitor bortezomib (Velcade) in patients with relapsed or refractory T-cell lymphoma.
    Zinzani, PL
    Tani, M
    Stefoni, V
    Alinari, L
    Marchi, E
    Fina, M
    Baccarani, M
    [J]. BLOOD, 2005, 106 (11) : 271B - 271B
  • [7] Phase II study of proteasome inhibitor bortezomib (Velcade®) in patients with relapsed/Refractory T-cell lymphoma:: Preliminary results.
    Zinzani, Pier Luigi
    Tani, Monica
    Musuraca, Gerardo
    Stefoni, Vittorio
    Marchi, Enrica
    Fina, Mariapaola
    Baccarani, Michele
    [J]. BLOOD, 2006, 108 (11) : 697A - 697A
  • [8] Marked clinical activity of the novel proteasome inhibitor bortezomib in patients with relapsed follicular (RL) and mantle cell lymphoma (MCL).
    O'Connor, OA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 578S - 578S
  • [9] The effect of proteasome inhibition with bortezomib(Velcade™) in B cell lymphoma cell lines
    Strauss, SJ
    Liu, W
    Maharaj, L
    Shringarpure, R
    Anderson, C
    Schenkein, D
    Lister, TA
    Joel, SP
    [J]. BRITISH JOURNAL OF CANCER, 2003, 88 : S65 - S65
  • [10] Effects of the Proteasome Inhibitor Bortezomib in Combination with Chemotherapy for the Treatment of Mantle Cell Lymphoma: A Meta-analysis
    Li, Shi-Jun
    Hao, Jian
    Mao, Yu
    Si, Yu-Ling
    [J]. TURKISH JOURNAL OF HEMATOLOGY, 2020, 37 (01) : 13 - 19
12345